Industry news

• Matching Personal and Company Success

  08 February 2019 Rita C. Peters / BoiPharm International

  The biopharma industry has found itself under political and societal microscopes in recent years, as executives search for answers to criticisms about high drug prices, shortages of vital therapies, and the industry’s role in the opioid epidemic. Meanwhile, a record number of new drug approvals and the emergence of innovative therapies demonstrate the potential of bio/pharma R&D efforts.

• Pharma CEOs enthuse about Trump's plan to shake up drug rebates

  08 February 2019 Eric Sagonowsky / FiercePharma

  Sweep out drug rebates for patient discounts instead? Big Pharma CEOs are all over it. A week after the Trump administration proposed ending drug rebates in federal health programs—and then urged Congress to extend that plan to commercial insurance—supply chain players are hitting back. The pharmacy benefit manager (PBM) industry has even launched an ad campaign.

• New Law, Control Russian Med Products

  07 February 2019 GMP News

  The President of the Russian Federation has signed Federal Law no. 511-FZ “On amendments to certain legislative acts of the Russian Federation”/ According to the new law, the regulator (Roszdravnadzor) has been granted a new function to carry out controlled purchases from retailers at any time without warning the retailer.

• Importance of Introducing Forced Licensing in Russia

  07 February 2019 GMP News

  Many international experts and scholars underline that excessive imbalanced protection of intellectual property can prevent development of innovations and scientific-and-technological progress. In this context, measures towards protecting intellectual property must be balanced by relevant opportunities, - stated Head of FAS Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev at the X Gaidar Forum.

• IQVIA Launches Services for Emerging Biopharma Needs

  06 February 2019 GMP News

  IQVIA has launched IQVIA Biotech and its new approach to providing clinical and commercial services for small biotech and biopharma companies. The solutions suite will provide simplified operating procedures, specialized teams, and services to help biopharma clients reach their drug development and commercialization milestones. IQVIA Biotech aims to deliver a transparent and streamlined process from initial planning to trial design and implementation to market launch and commercialization.

• Russia to Inspect British Pharma Manufacturers

  06 February 2019 GMP News

  The Russian Ministry of Industry and Trade’s State Institute of Drugs and Good Practices plans to inspect five British pharmaceutical manufacturers for compliance with GMP standards in 2019. That’s according to the institute’s director, Vladislav Shestakov.

• FDA Looks to Advance Complex Generics

  05 February 2019 BioPharm International

  On January 30, 2019, FDA Commissioner Scott Gottlieb, MD announced the agency would be publishing a series of guidance documents to address the specific challenges involved in the development of generic versions of complex drugs.  These guidance documents will be part of the agency’s Drug Competition Action Plan.

• The Global Use of Medicine in 2019 and Outlook to 2023 / Forecasts and Areas to Watch

  04 February 2019 IQVIA Institute for Human Data Science Study

  The global pharmaceutical market will exceed $1.5 trillion by 2023 growing at a 3−6% compound annual growth rate over the next five years. The key drivers of growth will continue to be the United States and pharmerging markets with 4−7% and 5–8% compound annual growth, respectively. In the United States, overall spending growth is driven by a range of factors including new product uptake and brand pricing, while it is offset by patent expiries and generics.

• Global Medicine Spending to Top $1.5 Trillion by 2023

  04 February 2019 BioPharm International

  Global drug spending will reach $1.2 trillion in 2018 and is expected to top $1.5 trillion by 2023, according to a study from the IQVIA Institute for Human Data Science Study, released on Jan. 29, 2019. The projected 2023 spending level, up 50% from 2016, will be reached despite lower growth of 3–6% on an annual compound basis compared to 6.3% over the past five years.

• UK and Russia’s Medicines Regulators Signed MoU

  04 February 2019 GMP News

  The Medicines and Healthcare products Regulatory Agency (MHRA) has signed a Memorandum of Understanding (MoU) with its Russian counterpart; the State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of the Russian Federation.